Chimeric antigen receptor natural killer(CAR-NK)cell therapy,as an emerging cellular immunotherapy strategy,has demonstrated a broader clinical application potential compared to CAR-T cell therapy due to its high safety profile and the unique advantages of'off-the-shelf'preparation.This article thoroughly discusses the antitumor mechanisms of CAR-NK cells,elucidating their targeted recognition mechanism,inherent cytotoxic activity,and the latest advancements in optimizing specific receptors to enhance their adaptability within the tumor microenvironment.Additionally,it provides an in-depth analysis of the advantages and challenges of various sources for CAR-NK cells,including peripheral blood,umbilical cord blood,induced pluripotent stem cells(iPSCs),and NK-92 cells,while summarizing their major challenges in the tumor immune microenvironment,such as insufficient persistence,immune suppression,and antigen heterogeneity.Finally,this article presents the therapeutic potential,limitations,and future perspectives of CAR-NK therapy in treating solid tumors,with a focus on its ongoing development and clinical translation.

In 2024,significant progress has been made in the field of immunology and inflammation,contributing to a series of important research achievements in immunology theories and translational applications.These latest immunological research achieve-ments have deepened our understanding of the fundamental principles of immunity and inflammation,laying a fundamental basis for re-vealing the mechanisms of autoimmune diseases,inflammatory diseases,and tumors,and developing new and effective treatment strategies.In this article,we summarized some of the representative advances in immunology research at home and abroad in 2024,and discussed the future challenges and directions.

In 2024,significant progress has been made in the field of immunology and inflammation,contributing to a series of important research achievements in immunology theories and translational applications.These latest immunological research achieve-ments have deepened our understanding of the fundamental principles of immunity and inflammation,laying a fundamental basis for re-vealing the mechanisms of autoimmune diseases,inflammatory diseases,and tumors,and developing new and effective treatment strategies.In this article,we summarized some of the representative advances in immunology research at home and abroad in 2024,and discussed the future challenges and directions.

Objective To investigate the therapeutic effects of bone marrow mesenchymal stem cells (BMSCs) for radiation-induced lung injury (RILI) and the underlying mechanism. Methods Forty-five healthy adult male C57BL/6 mice were randomly divided into control, model, and BMSCs groups. The model and BMSCs groups received a single irradiation dose of 20 Gy to the chest, while the control group did not receive X-ray irradiation. For the BMSCs group, an injection of 1 × 10⁶ BMSCs cells was administered via the tail vein within 6 h after irradiation. In the 5th week, the lung tissue was taken to observe pathological changes with HE staining; examine the expression of the inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) with immunohistochemical staining; observe the polarization of macrophages with immunofluorescence staining; and measure the expression of the epithelial-mesenchymal transition markers E-cadherin, N-cadherin, and vimentin proteins by Western blot. Results After radiation, the model group developed pulmonary vasodilation and congestion with septal thickening and inflammatory cell infiltration, and these changes were markedly reduced in the BMSCs group. The model group showed significantly down-regulated expression of IL-6 and TNF-α compared with significantly increased levels in the model group (P < 0.01, P < 0.05). Treatment with BMSCs significantly increased the polarization of lung macrophages towards the M2 type, while significantly decreasing the abnormally increased N-cadherin and vimentin levels in RILI mice (P < 0.05, P < 0.01). Conclusion BMSCs have therapeutic effects for RILI mice, which may be through promoting macrophage polarization from M1 to M2.

Objective To investigate the role of hydrogen therapy in reducing radiation-induced lung injury and the specific mechanism. Methods Forty C57BL/6 mice were randomly divided into four groups: normal control group, model group, hydrogen therapy group I, and hydrogen therapy group II. A mouse model of radiation-induced lung injury was established. The pathological changes in the lung tissue of the mice were examined with HE staining. Immunofluorescence staining was used to detect the expression of surface markers of M1 and M2 macrophages to observe macrophage polarization. The expression of interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and IL-10 in the lung tissue was measured by immunohistochemistry. The expression of nuclear factor-kappa B (NF-κB) p65 and phosphorylated NF-κB (P-NF-κB) p65 was measured by Western blot. Results HE staining showed that compared with the control group, the model group exhibited alveolar septal swelling and thickening, vascular dilatation and congestion, and inflammatory cell infiltration in the lung tissue; the hydrogen groups had significantly reduced pathological damage and inflammatory response than the model group, with more improvements in hydrogen group II than in hydrogen group I. Immunohistochemical results showed that compared with those in the control group, the levels of the inflammatory cytokines IL-6 and TNF-α were significantly increased in the model group; the hydrogen groups showed significantly decreased IL-6 and TNF-α levels and a significantly increased level of the anti-inflammatory factor IL-10 than the model group, which were more marked in hydrogen group II than in hydrogen group I. Immunofluorescence results showed that compared with the control group, the expression of the surface marker of M1 macrophages in the model group was significantly upregulated; the hydrogen groups showed significantly downregulated M1 marker and significantly upregulated M2 marker, and hydrogen group II showed significantly increased M2 marker compared with hydrogen group I. Western blot results showed that compared with that in the control group, the ratio of P-NF-κB p65/NF-κB p65 in the model group was significantly increased; the P-NF-κB p65/NF-κB p65 ratio was significantly reduced in the hydrogen groups than in the model group, and was significantly lower in hydrogen group II than in hydrogen group I. Conclusion Hydrogen inhalation therapy may reduce the inflammatory response of radiation-induced lung injury by inhibiting the NF-κB signaling pathway to promote the polarization of the macrophage M1 subtype to the M2 subtype.

In 2023,numerous theoretical advancements and technological breakthroughs have been achieved in the field of immunology research.In this article,we summarized representative research achievements in the field of immunology both domestically and internationally in 2023,and discussed the challenges and opportunities for future research.

RNA结合蛋白（RBP）由于其独特的生物学功能，目前已经成为肿瘤生物治疗相关靶点筛选的宠儿，很可能为肿瘤生物治疗带来新的机遇。RBP能调控肿瘤细胞及肿瘤微环境免疫细胞和间质细胞的DNA-RNA-蛋白质相互作用网络，进而广泛影响肿瘤发生发展、抗肿瘤免疫应答及肿瘤免疫逃逸过程，目前RBP相关肿瘤生物治疗的研发，主要聚焦在治疗性疫苗、免疫细胞治疗、表观调控治疗等方面，部分研发成果已处于临床试验阶段。随着新理论、新技术的发展以及研究模式的创新，靶向RBP的治疗逐渐摆脱了既往靶向难、疗效欠佳的困局，迎来了新的机遇，通过改良精准靶向和优化组合用药等新策略，为肿瘤生物治疗注入了新的活力，对精准个体化医疗的发展具有重要意义。

With the development of new technology and the innovation of research mode, tumor immunological research has achieved rapid development, and tumor immunotherapy has also shown remarkable clinical efficacy, jointly promoting the improvement of tumor immunology from mechanism research to clinical transformation and from single discipline to multi-disciplinary integration. However, multiple challenges still exist in tumor immunological research, such as the animal model replication for clinical tumor study, the complexity of tumor intrinsic regulation and its relationship with host microenvironment, and the screening of immunotherapy targets and the prediction of treatment effect. These problems limit the further development and application of tumor immunology, but also bring research opportunities to basic and clinical immunology researchers. Therefore, this review summarizes the research status and challenges as well as looks into the future of tumor immunity and immunotherapy in five aspects: the change of research model,the innovation of mechanism, the exploration of research objects, the screening and evaluation of therapeutic targets, as well as the application and innovation of new technologies.

TET2, a member of ten-eleven translocation (TET) family as α-ketoglutarate- and Fe

长链非编码RNA（lncRNA）是一类长度大于200 nt、且不编码的RNA。lncRNA已被证明与人类疾病紧密相关，尤其 是肿瘤发生发展。研究表明，肿瘤中一些异常表达的lncRNA可以通过不同的信号通路， 如Wnt/β-catenin信号通路，促进肿瘤进 展过程。在不同肿瘤组织中具有特异性表达特征的lncRNA与Wnt/β-catenin信号通路之间的相互作用显示出其作为新的生物标 志物和治疗靶点的潜能。本文就Wnt/β-catenin信号通路相关lncRNA通过调控Wnt/β-catenin信号转导，影响不同肿瘤类型发生 发展的作用进行综述。本文结果或可为临床肿瘤诊断和治疗提供新的思路。